Collaborative Research Centres

Kyverna Therapeutics Names Georg Schett, M.D., and Peter A. Merkel, M.D., MPH, to Scientific Advisory Board

Retrieved on: 
Tuesday, August 23, 2022
CEO, Regulation, Program, Regulatory T cell, Hospital of the University of Pennsylvania, University, Professor, Epidemiology, Internal medicine, NIH, CD19, Patient, Synthetic biology, Lupus nephritis, German Research Foundation, Scleroderma, Department, Autoimmunity, BMBF, Hospital, Yale University, Industry, MPH, Degenerative disease, CAR, Therapy, Checkpoint, Peter's Food Services, Principal, Multimedia, Internal, National academy, Coronavirus Scientific Advisory Board (Turkey), Amgen, Trustee, Collaborative Research Centres, Science, Vasculitis, National, Harvard University, Novo Nordisk Foundation, DFG, Vaccine, Pharmaceutical industry, Wood drying, Research, Rheumatology, Medicine, Arthritis, Inflammation

EMERYVILLE, Calif., Aug. 23, 2022 /PRNewswire/ -- Kyverna Therapeutics ("Kyverna"), a cell therapy company engineering a new class of therapies for serious autoimmune diseases, today announced the appointment of Georg Schett, M.D., Professor and Head of the Department of Internal Medicine 3, and Vice President of Research, Friedrich-Alexander University, Erlangen-Nürnberg, Erlangen, Germany, and Peter A. Merkel, M.D., MPH, Chief of Rheumatology and Professor of Medicine and Epidemiology at the University of Pennsylvania, as Scientific Advisors.

Key Points: 
  • "We are thrilled to have Georg and Peter, two internationally recognized experts in rheumatic and autoimmune diseases, join our Scientific Advisory Board," said Dominic Borie, M.D., Ph.D., President and CEO of Kyverna.
  • Prof. Dr. Schett's interests include basic, translational, and clinical research on molecular and cellular pathogenesis of rheumatic and autoimmune diseases.
  • Kyverna Therapeutics is a cell therapy company engineering a new class of therapies for autoimmune and inflammatory diseases.
  • By offering more than one mechanism for taming autoimmunity, Kyverna is positioned to transform how autoimmune diseases are treated.